Skip to main content
Molecular Cancer logoLink to Molecular Cancer
. 2026 Feb 20;25:40. doi: 10.1186/s12943-026-02592-y

Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Chen‑xing Zhao 1,#, Zi‑xun Yan 2,#, Jing‑jing Wen 1,#, Di Fu 2, Peng‑peng Xu 2, Li Wang 2,3, Shu Cheng 2, Jian‑da Hu 1,✉, Wei‑li Zhao 2,3,✉
PMCID: PMC12924337  PMID: 41721413

Correction : Mol Cancer 20, 153 (2021)

https://doi.org/10.1186/s12943-021-01458-9

Following the publication of the original article [1], the authors noticed a similarity in the DAPI staining and merge images between the Untreated_Farage-circEAF2 (FC-U) group and the Epirubicin_Farage-vector (FCV-E) group in Figure 6B. After a thorough re-examination of the original data, authors found the problem might have happened in the data acquisition. They took several pictures for each sample, but due to the similar compose type of file names, might mislabeled the No.1 of Farage-circEAF2 in untreated group (noted as FC-U#1) as No.1 of Farage-vector in Epirubicin group (noted as FCV-E#1), resulting in other yield of picture of FC-U cells was mistakenly reused as FCV-E cells. These errors have been corrected in the revised Fig.6B as shown below.

Corrected Figure 6:

graphic file with name 12943_2026_2592_Figa_HTML.jpg

Footnotes

Chen‑xing Zhao, Zi‑xun Yan and Jing‑jing Wen contributed equally to this work.

Contributor Information

Jian‑da Hu, Email: drjiandahu@163.com.

Wei‑li Zhao, Email: zhao.weili@yahoo.com.

Reference

  • 1.Zhao Cx, Yan Zx, Wen Jj, et al. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis. Mol Cancer. 2021;20:153. 10.1186/s12943-021-01458-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Cancer are provided here courtesy of BMC

RESOURCES